Building on the success of its inaugural event, the 2025 UCB HS Summit focused on amplifying the patient voice and tackling critical unmet needs in the HS community.

2025年UCB HS峰会基于其首届活动的成功，聚焦于放大患者声音，并解决HS社区中关键的未满足需求。

The event brought together over 100 people from across the HS community on the UCB Atlanta campus and featured interactive discussions and educational workshops focused on storytelling, wellness, nutrition, and advocating for care.

该活动在UCB亚特兰大校区聚集了来自HS社区的100多人，并举办了围绕讲故事、健康、营养以及倡导护理的互动讨论和教育研讨会。

Summit sessions also focused on expanding and optimizing earlier treatment of individuals living with moderate-to-severe HS.

峰会会议还侧重于扩大和优化对中度至重度HS患者的早期治疗。

BIMZELX

BIMZELX

®

®

(bimekizumab-bkzx) can deliver transformative relief of moderate-to-severe hidradenitis suppurativa (HS) symptoms, and patients can start to get themselves back.

(bimekizumab-bkzx) 能够显著缓解中度至重度化脓性汗腺炎 (HS) 症状，患者可以开始恢复自我。

1

1

In two clinical studies of adult patients with moderate-to-severe HS, around 5 in 10 people saw a 50% reduction in the number of inflamed nodules and abscesses, with no increase in abscesses or tunnels at 16 weeks, vs. around 3 in 10 taking placebo.

在针对中度至重度HS成人患者的两项临床研究中，约十分之五的患者在16周内炎性结节和脓肿数量减少了50%，且脓肿或窦道没有增加，而服用安慰剂的患者中仅有十分之三达到这一效果。

1

1

ATLANTA

亚特兰大

,

，

Aug. 5, 2025

2025年8月5日

/PRNewswire/ -- UCB, a global biopharmaceutical company, hosted its 2025 Hidradenitis Suppurativa (HS) Summit, which aimed to create a community forum for open discussion about HS, a dermatologic disease that remains both underdiagnosed and often misdiagnosed.

/PRNewswire/ -- 全球生物制药公司UCB举办了2025年化脓性汗腺炎（HS）峰会，旨在为HS创建一个社区论坛，进行公开讨论。HS是一种皮肤病，仍然存在诊断不足和常常误诊的情况。

2-3

2-3

By bringing stakeholders together, UCB sought to foster a deeper understanding of HS and address the challenges associated with it.

通过将利益相关者聚集在一起，UCB旨在加深对HS的理解并解决与其相关的挑战。

Continue Reading

继续阅读

UCB U.S. Immunology leaders, including Rhonda Peebles (VP & Head of U.S. Dermatology), Dr. Jeffrey Stark (VP & Head of Medical Immunology, U.S.), and Camille Lee (Head of U.S. Immunology), are joined by Dr. Vivian Shi, professor at the University of Washington (UW) Department of Dermatology and a board-certified dermatologist at the UW Medical Center–Roosevelt Dermatology Center, in an opening panel discussion at the UCB HS Summit dedicated to advancing the care of hidradenitis suppurativa (HS)..

包括罗纳·皮布尔（副总裁兼美国皮肤科负责人）、杰弗里·斯塔克博士（副总裁兼美国医学免疫学负责人）和李凯米尔（美国免疫学负责人）在内的UCB美国免疫学领导者，与华盛顿大学（UW）皮肤科系教授、UW医学中心罗斯福皮肤科中心认证皮肤科医生史薇薇博士一同出席了在UCB HS峰会的开幕专题讨论会，该峰会致力于推进化脓性汗腺炎（HS）的护理。

Brittany Blair, U.S. Head of Patient Strategy & Solutions for Immunology at UCB, leads the panel discussion “From Spotlight to Story: The HS Experience Unscripted” at the UCB HS Summit. This insightful session features HS patients featured in the UCB direct-to-consumer advertising campaign, Imani, Chaquira, Hannah, and Joey, who share their authentic experiences with HS – a severe dermatologic disease..

布列塔尼·布莱尔（Brittany Blair），UCB美国免疫学患者战略与解决方案主管，在UCB HS峰会上主持了题为“从聚光灯到故事：HS的真实体验”的小组讨论。这场富有洞察力的会议邀请到了参与UCB直接面向消费者的广告活动中的HS患者伊玛尼、查基拉、汉娜和乔伊，他们分享了自己与HS（一种严重的皮肤病）的真实经历。

HS patients Chaquira, Joey, Imani, Gabrielle, and Hannah immerse themselves in the engaging activities like a photo booth at the UCB HS Summit.

HS 学生查基拉、乔伊、伊玛尼、加布里埃尔和汉娜在 UCB HS 峰会上沉浸于诸如照片亭等引人入胜的活动之中。

The UCB HS Summit took place

UCB高中峰会举行

August 1-2, 2025

2025年8月1日至2日

, at UCB's

，在UCB的

Atlanta

亚特兰大

campus. The event featured discussions led by dermatologists, advanced practice providers, HS advocacy groups, and patients, sharing personal stories and providing continued education to advance understanding of HS. Key takeaways emphasized the power of patient storytelling in conveying the authentic, day-to-day experiences of living with HS.

校园。该活动由皮肤科医生、高级执业医师、HS倡导团体和患者主导讨论，分享个人故事并提供继续教育，以增进对HS的理解。关键要点强调了患者讲述故事的力量，传达了患有HS的真实日常生活体验。

Participants recognized that while each individual's journey is unique and involves distinct challenges, the community stands united in its commitment to driving meaningful change..

与会者认识到，虽然每个人的旅程都是独特的，并且面临不同的挑战，但整个团队在推动有意义的变革方面仍然团结一致。

'The ongoing unmet needs in patient communities like those affected by HS drive our commitment to scientific innovation,' said

“像HS这样的患者群体中持续未满足的需求推动了我们对科学创新的承诺，”

Camille Lee

李卡米尔

, Head of U.S. Immunology, UCB. 'Building on the success of UCB's HS Summit last year, we are proud to host the UCB HS Summit, bringing together patients, caregivers, advocates, and healthcare providers during a period of promising treatment options, including BIMZELX

美国免疫学主管，UCB。 “在去年UCB的HS峰会成功的基础上，我们很自豪地举办UCB HS峰会，将患者、护理人员、倡导者和医疗保健提供者聚集在一起，在一个充满希望的治疗选择时期，包括BIMZELX。”

®

®

. Despite these positive developments, we recognize the ongoing challenges the community faces, such as the need for more timely diagnoses, earlier treatment, and ongoing education.'

尽管有这些积极的发展，我们认识到社区面临的持续挑战，例如需要更及时的诊断、更早的治疗以及持续的教育。

The Summit kicked off with a fireside chat exploring the evolution of the HS landscape in recent years and highlighting the importance of partnership with the HS community to advance care. A joint session between clinicians and patients followed, fostering meaningful discussions around treatment and unmet needs, navigating the healthcare system, and collaborative ways to best support patients.   .

峰会以一场炉边谈话拉开帷幕，探讨了近年来HS领域的发展，并强调了与HS社区合作以推进护理的重要性。随后进行了一个由临床医生和患者共同参与的联合会议，围绕治疗和未满足的需求、医疗系统导航以及如何以协作的方式最好地支持患者展开了有意义的讨论。

HS is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.

HS 是一种慢性、疼痛且可能致残的炎性皮肤病，与全身性表现相关。

2-3

2-3

Common symptoms include inflamed nodules that look like boils and abscesses.

常见症状包括看起来像疖子和脓肿的炎性结节。

2

2

These can occur anywhere hair follicles are found, but usually develop in areas where skin rubs together, like armpits, the groin area, and the inner thighs.

这些部位可能出现在任何有毛囊的地方，但通常会发生在皮肤相互摩擦的区域，如腋窝、腹股沟和大腿内侧。

3

3

HS lesions tend to heal slowly and come back often, leading to tunnels under the skin and scarring.

HS 病变愈合缓慢且经常复发，导致皮肤下形成隧道并留下疤痕。

2,4

2,4

BIMZELX is the first and only approved treatment for adults with moderate-to-severe HS specifically designed to target interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines that drive the inflammatory process.

BIMZELX 是首个且唯一获批用于治疗中度至重度 HS 成人的药物，专门设计用于靶向白细胞介素 17A (IL-17A) 和白细胞介素 17F (IL-17F)，这两种关键的细胞因子驱动了炎症过程。

1

1

BIMZELX is approved in the U.S. in five indications, including HS.

BIMZELX在美国已获批五项适应症，包括HS。

1

1

UCB is proud to contribute to advancing the understanding of HS, addressing the unmet needs of those living with the disease, and raising standards of care across a range of IL-17 mediated diseases. To learn more about UCB's commitment to patients impacted by dermatologic diseases, visit

UCB很自豪能够为推进对HS的理解、满足那些患有该疾病的人未被满足的需求，以及提高多种IL-17介导疾病的护理标准做出贡献。要了解更多关于UCB对受皮肤病影响患者的承诺，请访问

UCB-USA.com/innovation/dermatology

UCB-USA.com/innovation/皮肤病学

.

。

About Hidradenitis Suppurativa

关于化脓性汗腺炎

Hidradenitis suppurativa (HS) is a chronic, painful, and potentially debilitating inflammatory skin disease that is associated with systemic manifestations.

化脓性汗腺炎（HS）是一种慢性、疼痛且可能致残的炎症性皮肤病，与全身性表现相关。

2-3

2-3

The main symptoms are nodules, abscesses, and pus-discharging draining tunnels (or sinus tracts leading out of the skin) that typically occur in the armpits, groin, and buttocks, but can occur anywhere on the body there are hair follicles.

主要症状是结节、脓肿和流脓的引流隧道（或通向皮肤外的窦道），通常出现在腋下、腹股沟和臀部，但身体任何有毛囊的部位都可能出现。

2-3

2-3

People with HS experience flare-ups of the disease as well as severe pain, which can have a major impact on quality of life.

患有 HS 的人会经历疾病的爆发以及剧烈的疼痛，这对生活质量有重大影响。

2-3

2-3

HS develops in early adulthood and affects approximately one percent of the population in most studied countries.

HS 发展于成年早期，影响大多数研究国家中约百分之一的人口。

2-3

2-3

About BIMZELX

关于BIMZELX

®

®

(bimekizumab-bkzx)

（比美珠单抗-bkzx）

BIMZELX is a humanized monoclonal IgG1 antibody that is designed to selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines driving inflammatory processes.

BIMZELX 是一种人源化的单克隆 IgG1 抗体，旨在选择性抑制白细胞介素 17A（IL-17A）和白细胞介素 17F（IL-17F），这两种关键的细胞因子会驱动炎症过程。

1

1

IL-17A and IL-17F are key contributors of chronic inflammation and damage across multiple tissues, with IL-17F increasing over time.

IL-17A 和 IL-17F 是导致多个组织慢性炎症和损伤的关键因素，其中 IL-17F 会随着时间的推移而增加。

1,5-7

1,5-7

IL-17F is over-expressed in skin and highly elevated in the serum of patients with psoriasis (PSO), psoriatic arthritis (PsA), non-radiographic axial spondyloarthritis (nr-axSpA), ankylosing spondylitis (AS), and hidradenitis suppurativa (HS).

IL-17F在银屑病（PSO）、银屑病关节炎（PsA）、非放射学中轴型脊柱关节炎（nr-axSpA）、强直性脊柱炎（AS）和化脓性汗腺炎（HS）患者的皮肤中过表达，在血清中显著升高。

1,5-8

1,5-8

The approved indications for BIMZELX in the U.S. are:

美国批准的BIMZELX适应症为：

1

1

Plaque psoriasis: BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

斑块状银屑病：BIMZELX 适用于系统治疗或光疗的中度至重度斑块状银屑病成人患者的治疗。

Psoriatic arthritis: BIMZELX is indicated for the treatment of adult patients with active psoriatic arthritis

银屑病关节炎：BIMZELX 适用于治疗活动性银屑病关节炎的成年患者。

Non-radiographic axial spondyloarthritis: BIMZELX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation

非放射学中轴型脊柱关节炎：BIMZELX 适用于治疗具有炎症客观体征的活动性非放射学中轴型脊柱关节炎成年患者。

Ankylosing spondylitis: BIMZELX is indicated for the treatment of adult patients with active ankylosing spondylitis

强直性脊柱炎：BIMZELX 适用于治疗活动性强直性脊柱炎的成年患者。

Hidradenitis suppurativa: BIMZELX is indicated for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa

化脓性汗腺炎：BIMZELX 适用于治疗中度至重度化脓性汗腺炎的成年患者。

BIMZELX U.S. IMPORTANT SAFETY INFORMATION

BIMZELX 美国重要安全信息

IMPORTANT SAFETY INFORMATION

重要安全信息

Suicidal Ideation and Behavior

自杀意念与行为

BIMZELX (bimekizumab-bkzx) may increase the risk of suicidal ideation and behavior (SI/B). A causal association between treatment with BIMZELX and increased risk of SI/B has not been definitively established. Prescribers should weigh the potential risks and benefits before using BIMZELX in patients with a history of severe depression or SI/B.

BIMZELX（比美珠单抗-bkzx）可能会增加自杀意念和行为（SI/B）的风险。尚未明确证明使用BIMZELX治疗与SI/B风险增加之间存在因果关系。在有严重抑郁或SI/B病史的患者中使用BIMZELX之前，处方者应权衡潜在的风险和益处。

Advise monitoring for the emergence or worsening of depression, suicidal ideation, or other mood changes. If such changes occur, instruct to promptly seek medical attention, refer to a mental health professional as appropriate, and re-evaluate the risks and benefits of continuing treatment..

建议监测抑郁、自杀念头或其他情绪变化的出现或恶化。如果发生此类变化，应指示患者及时就医，根据情况转诊给心理健康专业人士，并重新评估继续治疗的风险和益处。

Infections

感染

BIMZELX may increase the risk of infections, including serious infections. Do not initiate treatment with BIMZELX in patients with any clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing BIMZELX.

BIMZELX可能会增加感染风险，包括严重感染。在任何临床上重要的活动性感染得到解决或充分治疗之前，请勿对患者开始使用BIMZELX进行治疗。对于患有慢性感染或有反复感染史的患者，在开BIMZELX处方前应权衡其风险与收益。

Instruct patients to seek medical advice if signs or symptoms suggestive of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, monitor the patient closely and do not administer BIMZELX until the infection resolves. .

指导患者如果出现提示有临床重要感染的体征或症状，应寻求医疗建议。如果患者发生这样的感染或对标准疗法无反应，应密切监测患者，并且在感染解决之前不要给予BIMZELX。

Tuberculosis

结核病

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with BIMZELX. Avoid the use of BIMZELX in patients with active TB infection. Initiate treatment of latent TB prior to administering BIMZELX. Consider anti-TB therapy prior to initiation of BIMZELX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed.

在开始使用BIMZELX治疗前，应评估患者是否存在结核病（TB）感染。避免在活动性结核感染患者中使用BIMZELX。在给予BIMZELX之前，应先开始治疗潜伏性结核。对于有潜伏性或活动性结核病史且无法确认已接受足够疗程的患者，应在开始使用BIMZELX前考虑进行抗结核治疗。

Closely monitor patients for signs and symptoms of active TB during and after treatment. .

在治疗期间和治疗后密切监测患者是否有活动性结核病的体征和症状。

Liver Biochemical Abnormalities

肝脏生化异常

Elevated serum transaminases were reported in clinical trials with BIMZELX. Test liver enzymes, alkaline phosphatase, and bilirubin at baseline, periodically during treatment with BIMZELX, and according to routine patient management. If treatment-related increases in liver enzymes occur and drug-induced liver injury is suspected, interrupt BIMZELX until a diagnosis of liver injury is excluded.

在BIMZELX的临床试验中报告了血清转氨酶升高。在使用BIMZELX治疗前、治疗期间定期以及根据常规患者管理要求，检测肝酶、碱性磷酸酶和胆红素。如果出现与治疗相关的肝酶升高并怀疑药物性肝损伤，应中断BIMZELX治疗，直至排除肝损伤诊断。

Permanently discontinue use of BIMZELX in patients with causally associated combined elevations of transaminases and bilirubin. Avoid use of BIMZELX in patients with acute liver disease or cirrhosis. .

对于转氨酶和胆红素同时升高的患者，永久停止使用BIMZELX。避免在急性肝病或肝硬化患者中使用BIMZELX。

Inflammatory Bowel Disease

炎症性肠病

Cases of inflammatory bowel disease (IBD) have been reported in patients treated with IL-17 inhibitors, including BIMZELX. Avoid use of BIMZELX in patients with active IBD. During BIMZELX treatment, monitor patients for signs and symptoms of IBD and discontinue treatment if new onset or worsening of signs and symptoms occurs.

使用包括BIMZELX在内的IL-17抑制剂治疗的患者中已有炎症性肠病（IBD）病例报告。避免在活动性IBD患者中使用BIMZELX。在BIMZELX治疗期间，监测患者是否出现IBD的症状和体征，如果出现新发或症状体征加重的情况，应停止治疗。

.

。

Immunizations

免疫接种

Prior to initiating therapy with BIMZELX, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid the use of live vaccines in patients treated with BIMZELX.

在开始使用BIMZELX治疗之前，根据当前免疫指南完成所有适龄疫苗接种。避免在使用BIMZELX治疗的患者中使用活疫苗。

Most Common Adverse Reactions

最常见的不良反应

Most common (≥ 1%) adverse reactions in plaque psoriasis and hidradenitis suppurativa include upper respiratory tract infections, oral candidiasis, headache, injection site reactions, tinea infections, gastroenteritis, herpes simplex infections, acne, folliculitis, other candida infections, and fatigue. .

最常见的（≥1%）斑块型银屑病和化脓性汗腺炎的不良反应包括上呼吸道感染、口腔念珠菌病、头痛、注射部位反应、癣感染、胃肠炎、单纯疱疹感染、痤疮、毛囊炎、其他念珠菌感染和疲劳。

Most common (≥ 2%) adverse reactions in psoriatic arthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, and urinary tract infections.

银屑病关节炎最常见的（≥2%）不良反应包括上呼吸道感染、口腔念珠菌病、头痛、腹泻和尿路感染。

Most common (≥ 2%) adverse reactions in non-radiographic axial spondyloarthritis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, cough, fatigue, musculoskeletal pain, myalgia, tonsillitis, transaminase increase, and urinary tract infections.

非放射学中轴型脊柱关节炎最常见的（≥2%）不良反应包括上呼吸道感染、口腔念珠菌病、头痛、腹泻、咳嗽、疲劳、肌肉骨骼疼痛、肌痛、扁桃体炎、转氨酶升高和尿路感染。

Most common (≥ 2%) adverse reactions in ankylosing spondylitis include upper respiratory tract infections, oral candidiasis, headache, diarrhea, injection site pain, rash, and vulvovaginal mycotic infection.

最常见的（≥2%）强直性脊柱炎不良反应包括上呼吸道感染、口腔念珠菌病、头痛、腹泻、注射部位疼痛、皮疹和外阴阴道真菌感染。

Please see Important Safety Information below and full U.S. Prescribing Information at

请参阅下面的重要安全信息，并在美国处方信息中查看全部内容。

www.UCB-USA.com/Innovation/Products/BIMZELX

www.UCB-USA.com/创新/产品/BIMZELX

.

。

For further information, contact UCB:

如需更多信息，请联系UCB：

U.S. Communications

美国通信

Nicole Herga

尼科尔·赫尔加

T +1.773.960.5349

T +1.773.960.5349

email

电子邮件

Nicole.Herga@ucb.com

尼科尔·赫尔加@ucb.com

About UCB

关于UCB

UCB,

UCB，

Brussels, Belgium

比利时布鲁塞尔

(

(

www.ucb.com

www.ucb.com

) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 9,000 people in approximately 40 countries, the company generated revenue of €6.1 billion in 2024.

）是一家全球生物制药公司，专注于发现和开发创新药物和解决方案，以改变免疫系统或中枢神经系统严重疾病患者的生活。该公司在约40个国家拥有大约9000名员工，并在2024年实现了61亿欧元的收入。

Follow us on Twitter: @UCBUSA..

在Twitter上关注我们：@UCBUSA。

Forward looking statements

前瞻性声明

This document contains forward-looking statements, including, without limitation, statements containing the words 'potential', 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'continue' and similar expressions. These forward-looking statements are based on current plans, estimates and beliefs of management.

本文件包含前瞻性陈述，包括但不限于包含“潜在”、“相信”、“预期”、“预计”、“打算”、“计划”、“寻求”、“估计”、“可能”、“将”、“继续”等词语及类似表达的陈述。这些前瞻性陈述基于管理层当前的计划、估计和信念。

All statements, other than statements of historical facts, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, arbitration, political, regulatory or clinical results or practices and other such estimates and results.

所有声明，除历史事实声明之外，均可能被视为前瞻性声明，包括收入、营业利润率、资本支出、现金、其他财务信息、预期法律、仲裁、政治、监管或临床结果或实践以及其他此类估计和结果的预估。

By their nature, such forward-looking statements are not guaranteeing future performance and are subject to known and unknown risks, uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this document..

由于此类前瞻性陈述的性质，它们并不保证未来的表现，并且受到已知和未知风险、不确定性以及可能导致UCB的实际结果、财务状况、业绩或成就（或行业结果）与本文件中包含的此类前瞻性陈述明示或暗示的任何未来结果、业绩或成就存在重大差异的假设的影响。

Important factors that could result in such differences include but are not limited to: global spread and impacts of wars, pandemics and terrorism, the general geopolitical environment, climate change, changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms or within expected timing, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, safety, quality, data integrity or manufacturing issues, supply chain disruption and business continuity risks; potential or actual data security and data privacy breaches, or disruptions of UCB's information technology systems, product liability claims, challenges to patent protection for products or product candidates, competition from other products including biosimilars or disruptive technologies/business models, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in laws and/or rules pertaining to tax and duties or the administration of such laws and/or rules, and hiring, retention and compliance of employees.

可能导致此类差异的重要因素包括但不限于：战争、疫情和恐怖主义的全球蔓延及影响、总体地缘政治环境、气候变化、总体经济、商业和竞争状况的变化、无法获得必要的监管批准或未能在可接受的条件或预期时间内获得批准、与研发相关的成本、UCB在研或开发中产品前景的变化、未来司法裁决或政府调查的影响、安全性、质量、数据完整性或制造问题、供应链中断和业务连续性风险；潜在或实际的数据安全和隐私泄露，或UCB信息技术系统的中断、产品责任索赔、对产品或候选产品专利保护的挑战、来自其他产品（包括生物类似药或颠覆性技术/商业模式）的竞争、法律法规的变化、汇率波动、与税收和关税相关法律和/或规则及其管理的变化或不确定性，以及员工的招聘、留用和合规问题。

There is no guarantee that new product candidates will be discovered or identified in the pipeline, or that new indications for existing products will be developed and approved. Movement from concept to commercial product is uncertain; preclinical results do not guarantee safety and efficacy of product candidates in humans.

无法保证在研发管线中会发现或识别出新的产品候选者，也无法保证现有产品的新的适应症能够被开发和批准。从概念到商业产品的推进过程充满不确定性；临床前结果并不能保证产品候选者在人体中的安全性和有效性。

So far, the complexity of the human body cannot be reproduced in computer models, cell culture systems or animal models. The length of the timing to complete clinical trials and to get regulatory approval for product marketing has.

到目前为止，人体的复杂性无法在计算机模型、细胞培养系统或动物模型中重现。完成临床试验和获得产品上市监管批准的时间长度已经。

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are made only as of the date of this document, and do not reflect any potential impacts from the evolving event or risk as mentioned above as well as any other adversity, unless indicated otherwise.

鉴于这些不确定性，公众被提醒不要对这些前瞻性陈述给予任何过度依赖。这些前瞻性陈述仅在本文档发布之日作出，除非另有说明，否则并未反映上述不断演变的事件或风险以及任何其他不利因素的潜在影响。

The company continues to follow the development diligently to assess the financial significance of these events, as the case may be, to UCB..

公司继续认真跟进事态发展，以便根据具体情况评估这些事件对UCB的财务重要性。

UCB expressly disclaims any obligation to update any forward-looking statements in this document, either to confirm the actual results or to report or reflect any change in its forward-looking statements with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless such statement is required pursuant to applicable laws and regulations. .

UCB明确表示，除非适用法律法规要求，否则不承担更新本文件中任何前瞻性陈述的义务，无论该等更新是为了确认实际结果，还是为了报告或反映与其前瞻性陈述相关的任何变化，或反映任何基于该等陈述的事件、条件或情况的变化。

References

参考文献

BIMZELX

BIMZELX

®

®

(bimekizumab-bkzx) U.S. Prescribing Information.

(bimekizumab-bkzx) 美国处方信息。

https://www.ucb-usa.com/Innovation/Products/BIMZELX

https://www.ucb-usa.com/Innovation/Products/BIMZELX

. Accessed: August 2025.

访问时间：2025年8月。

Jemec GBE. Clinical practice. Hidradenitis suppurativa.

杰梅克 GBE。临床实践。化脓性汗腺炎。

N Engl J Med.

新英格兰医学杂志。

2012;366(2):158–64.

2012;366(2):158–64.

Sabat R, Jemec GBE, Matusiak L, et al. Hidradenitis suppurativa.

萨巴特 R、耶梅克 GBE、马图西亚克 L 等。化脓性汗腺炎。

Nat Rev Dis Primers.

Nat Rev Dis Primers.

2020;6(1):18.

2020；6（1）：18。

Ingram JR. The epidemiology of hidradenitis suppurativa.

英格拉姆 JR。化脓性汗腺炎的流行病学。

Br J Dermatol.

英国皮肤病学杂志。

2020;183(6):990-98. doi:10.1111/bjd.19435. Epub 2020

2020;183(6):990-98. doi:10.1111/bjd.19435. Epub 2020

Sep 3

9月3日

. PMID: 32880911.

PMID: 32880911。

Glatt S, Baeten D, Baker T et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.

Glatt S、Baeten D、Baker T 等。Bimekizumab 对银屑病关节炎中 IL-17A 和 IL-17F 的双重中和：来自临床前实验和随机安慰剂对照临床试验的证据表明 IL-17F 促进人类慢性组织炎症。

Ann Rheum Di

安·瑞姆·迪

s. 2018;77:523–32.

2018年；77卷：523-32页。

Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate-to-severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.

戈登 KB，弗oley P，克鲁格 JG，等。Bimekizumab在中至重度斑块型银屑病中的疗效与安全性（BE READY）：一项多中心、双盲、安慰剂对照的随机撤药三期试验。

Lancet

柳叶刀

. 2021;397(10273):475-486.

. 2021;397(10273):475-486.

Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate-to-severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.

Reich K, Papp KA, Blauvelt A, 等。Bimekizumab与Ustekinumab治疗中至重度斑块型银屑病（BE VIVID）：来自一项为期52周、多中心、双盲、活性对照和安慰剂对照的3期试验的疗效与安全性。

Lancet.

柳叶刀。

2021;397(10273):487-498.

2021；397（10273）：487-498。

Rumberger BE, Boarder EL, Owens SL, et al. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis.

Rumberger BE、Boarder EL、Owens SL 等。化脓性汗腺炎皮肤的转录组分析提示多种炎症通路在疾病发病机制中起作用。

Inflamm Res

炎症研究

. 2020;69(10):967-973.

. 2020;69(10):967-973.

US-BK-2500945

美国-BK-2500945

BIMZELX

BIMZELX

®

®

is a registered trademark of the UCB Group of Companies.

是UCB集团公司注册商标。

©2025 UCB, Inc.,

©2025 UCB, Inc.,

Smyrna, GA

乔治亚州士麦那

30080. All rights reserved.

30080. 保留所有权利。

SOURCE UCB

来源 UCB

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用